Security Snapshot

ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) Institutional Ownership

CUSIP: 682310875

13F Institutional Holders and Ownership History from Q2 2018 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

56

Shares (Excl. Options)

2,996,321

Price

$0.85

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock, no par value
Symbol
ONCY on Nasdaq
Shares outstanding
109,272,143
Price per share
$0.85
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
2,996,321
Total reported value
$2,605,560
% of total 13F portfolios
0%
Share change
+248,815
Value change
+$189,006
Number of holders
56
Price from insider filings
$0.85
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • ONCY - ONCOLYTICS BIOTECH INC - Common Stock, no par value is tracked under CUSIP 682310875.
  • 56 institutions reported positions in Q1 2026.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 61 to 56 between Q4 2025 and Q1 2026.
  • Reported value moved from $2,449,574 to $2,605,560.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 56 institutions filings for Q1 2026.

Open SEC Evidence

Security key

682310875

Latest holder period

Q1 2026

13F holders

56

13D/G owners

1

CIK / CUSIP context first

Open Q1 2026 holders ONCY full holder history ONCOLYTICS BIOTECH INC SEC filings ONCOLYTICS BIOTECH INC company facts ONCOLYTICS BIOTECH INC insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Significant Owners of ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Anson Funds Management LP 7% -26% $10,708,670 -$751,370 7,649,050 -6.6% Anson Funds Management LP 30 Sep 2025

As of 31 Mar 2026, 56 institutional investors reported holding 2,996,321 shares of ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY). This represents 2.7% of the company’s total 109,272,143 outstanding shares.

Institutional Holders of ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 2,996,321 $2,605,560 +$189,006 $0.85 56
2025 Q4 2,797,506 $2,449,574 -$295,679 $0.87 61
2025 Q3 2,820,198 $3,771,684 +$1,889,818 $1.40 56
2025 Q2 1,495,731 $1,150,336 +$116,133 $0.77 54
2025 Q1 1,364,360 $748,757 -$5,861 $0.55 50
2024 Q4 1,314,892 $1,206,107 +$64,784 $0.91 46
2024 Q3 999,534 $872,336 -$113,469 $0.87 40
2024 Q2 1,309,286 $1,297,302 -$118,709 $0.99 41
2024 Q1 1,409,004 $1,495,371 -$5,110,399 $1.06 35
2023 Q4 5,144,044 $6,944,143 -$1,456,985 $1.35 42
2023 Q3 6,216,229 $13,562,379 +$11,870,396 $2.18 32
2023 Q2 800,773 $2,085,599 -$679,945 $2.60 28
2023 Q1 1,103,514 $1,325,529 +$296,418 $1.20 30
2022 Q4 902,111 $1,482,300 +$321,702 $1.63 33
2022 Q3 714,327 $883,809 -$184,426 $1.23 28
2022 Q2 909,878 $911,763 +$188,561 $1.00 33
2022 Q1 697,567 $1,099,375 -$760,113 $1.58 29
2021 Q4 1,187,087 $1,652,710 +$287,570 $1.40 34
2021 Q3 903,524 $1,890,946 -$125,314 $2.09 32
2021 Q2 887,682 $2,434,336 -$773,341 $2.77 35
2021 Q1 1,038,987 $3,786,537 +$314,929 $3.81 36
2020 Q4 1,085,633 $2,586,529 +$776,286 $2.38 30
2020 Q3 776,299 $1,313,572 -$60,476 $1.69 27
2020 Q2 828,293 $1,562,243 +$487,963 $1.88 30
2020 Q1 590,438 $816,220 +$77,206 $1.39 28
2019 Q4 384,390 $1,816,270 +$231,441 $4.75 23
2019 Q3 391,100 $223,581 -$568,195 $0.58 12
2019 Q2 573,234 $975,780 +$645,305 $1.70 13
2019 Q1 193,664 $358,834 +$66,521 $1.87 17
2018 Q4 156,055 $282,469 -$180,670 $1.78 15
2018 Q3 184,782 $699,979 -$1,552,787 $3.83 16
2018 Q2 586,197 $3,220,392 +$3,220,392 $5.43 18
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .